BlackPeak Capital Leads EUR 20M Series B Funding Round for GenePlanet's Expansion in Clinical and Lifestyle Genetic Testing
- The company is a market leader in DNA testing in CEE with strong growth momentum in markets in Western Europe, Latin America, and Asia.
- GenePlanet’s genetic testing solutions focus on both clinical and lifestyle factors and the investment will enable the company to further establish itself as a leader in the genetic testing industry, benefiting from the growing interest in personalized medicine and proactive health management.
BlackPeak Capital, together with Darwin AG, Kolektor d.d., FMR d.o.o., and Designed Impact Ventures GmbH, has announced a series B investment of EUR 20 million in GenePlanet, a biotech company specializing in developing clinical, in particular non-invasive prenatal testing (“NIPT”), and lifestyle genetic testing solutions based on whole genome technology. NIPT is a widely encountered illustration of clinical solutions. It is designed to accurately identify specific chromosomal abnormalities in the fetus during the early stages of pregnancy (around 10 gestational weeks). In this segment, GenePlanet is the clear market leader in Central and Eastern Europe (“CEE”) and has started to enter new markets in W. Europe, Latin America, and Asia.
In addition, the company offers lifestyle tests that provide information about an individual's genetic predisposition to various conditions, including cancer and heart disease. It also offers insights into an individual’s genetic traits related to diet, exercise, sleep, stress, and other lifestyle factors.
The investment will enable GenePlanet to expand its product portfolio, make targeted add-on acquisitions in medical DNA testing, invest in big data infrastructure, and support its global expansion plans. The capital will also enable Geneplanet to further develop an advanced AI system for large-scale language models. This innovative platform will enable more sophisticated browsing and interpretation of the human genome, a step-change in personalized medicine that promises to bring significant health benefits to individuals worldwide. With the growing demand for personalized medicine and proactive health management, GenePlanet is well-positioned to benefit from the rising interest in genetic testing, particularly in health and wellness.
The investment in GenePlanet is a testimony to the company’s potential for growth and expansion. With the support of BlackPeak Capital and other investors, GenePlanet can accelerate its growth and development, providing innovative genetic testing solutions that have the potential to transform healthcare and improve people’s lives.
Niklas Pichler, who is Managing Partner of BlackPeak Capital and led this transaction, will join the board of GenePlanet to support GenePlanet in executing its growth plans.
GenePlanet is the leading CEE provider of preventive genetic tests, specialising in NIPT, cancer screening, and lifestyle DNA tests. The company was founded in 2008 with the vision of enabling more and more people around the world to discover their DNA.
With over 15 years of experience in the market, GenePlanet collaborates with over 1000 medical centres, doctors, and insurance companies to provide top-quality tests based on the latest scientific discoveries. The company’s tests are designed to empower individuals to take control of their and their baby’s health, as well as assist doctors with therapeutic procedures. GenePlanet adheres to the highest standards of quality and is constantly striving for new discoveries through its research and development efforts.
With a presence in more than 35 countries worldwide and over 100,000 satisfied customers, GenePlanet has been recognised as one of the 1000 fastest-growing companies in the EU by the Financial Times and one of the Top 35 EU Unicorns by the European Commission.
GenePlanet’s mission is to continue to provide cutting-edge genetic testing solutions that enable individuals to make informed decisions about their health and well-being.
For more info, please visit: https://geneplanet.com/eu
About Darwin AG
Darwin AG is a German holding company, providing insights in preventive, lifestyle genetic testing and produces individualized nutritional supplements and cosmetics based on such insights. Additionally, the company develops in-house technologies using artificial intelligence to interpret genetic data to give in-depth insights into the body and invests in innovative biotech and healthcare companies.
For more information, please visit https://darwin-biotech.com/.
About Kolektor d.d.
Kolektor is one of the leading Slovenian industrial, export-oriented companies. In 60 years, it has developed from a company with a few dozen employees, one product, one customer and one production location into a business system with three strong strategic business groups: Kolektor Mobility, Kolektor Technologies and Kolektor Construction. This network combines 40 companies in Slovenia and abroad, over 5500 employees and a wide portfolio of products and services. The mission of Kolektor is to thrive in the world of mobility, construction, energy, infrastructure, and digitization. Last year, it achieved a turnover of 1.1 billion euros. Within the scope of its financial group, Kolektor invests in health and social care, media, and tourism and catering.
For more information, please visit www.kolektor.com.
The main activities of FMR are establishing, managing and financing of subsidiaries, but it is active also in the field of different forms of long- and short-term financial investments and the investments into real estate and rental of its own real estate. The mission of FMR is to increase its assets every year through different long- and short-term financial investments and real estate investments, and thus also the value of the shareholders' assets, which they hold in the form of company shares.
For more information, please visit www.fmr.si.
Financial and Tax advisor: TPA Group
Legal advisor: Ulčar & Partners
Commercial Due Diligence: VINC Advisory
ESG Due Diligence: ERM Romania